Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antidepressant

or Benzodiazepine

or Psychostimulant

Use the filters below to narrow your results.

None (10) · Adderall, Adderall XR, Mydayis (1) · Anafranil (1) · Aurorix (1) · Captagon (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Dalmane (1) · Desoxyn (1) · Dexedrine (1) · Doral (1) · Edronax (1) · Fetzima (1) · Focalin, Focalin XR (1) · Halcion (1) · Lexotan (1) · Librium (1) · Ludiomil (1) · Marplan (1) · Mogadon (1) · Nardil (1) · Norpramin (1) · Onfi (1) · Parnate (1) · ProSom (1) · Restoril (1) · Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR (1) · Rohypnol (1) · Savella (1) · Serax (1) · Serzone (1) · Stablon (1) · Surmontil (1) · Tofranil (1) · Tranxene (1) · Valdoxan (1) · Versed (1) · Vivactil (1) · Xanax (1) · Zoloft (1)

Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · Irreversible non-selective MAO inhibitor (3) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Monoamine releasing agent (1) · Monoamine releasing agent, TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET) (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Prodrug of amphetamine + theophylline (1) · Reversible inhibitor of MAO-A (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport, net release of dopamine and norepinephrine (1) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1)

None (44) · 0.25 mg (1) · 2.5 mg IR, 5 mg XR, or 12.5mg Mydayis (1) · 25 mg (1) · 5 mg PO (1)

None (44) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · Desoxyn 5 mg tabs (1) · IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg (1)

None (44) · 10 mg/d (1) · 200 mg/d (1) · 25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label) (1) · XR = 40 or 60 mg/d; IR = 40 or 60 mg/d'"`UNIQ--ref-00000567-QINU`"' (1)

None (41) · Oral (6) · Oral (prescribed) (1) · transdermal (1)

None (42) · 20–60 min (oral) (1) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · 30–60 min (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · IR: 30–60 min; XR: 1–2 h to peak effect (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

None (42) · 6 h (immediate-release); ~11 h (extended-release) (1) · Chronic daily dosing (1) · IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time (1) · IR 4–6 h; XR 10–12 h; Mydayis 14–16 h (1) · IR 4–6 h; XR 8–12 h (1) · Long (1)

None (42) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · 2.2 h (IR parent); ~3 h (XR parent) (1) · 2–3 h (parent compound) (1) · D-amphetamine ~10 h; L-amphetamine ~13 h (adults) (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (42) · 80-90% oral (1) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · ~22–25% (1) · ~30% (high first-pass) (1) · ~50% (highly variable) (1) · ~75–90% (oral) (1)

None (41) · Category C (3) · Category C (per Desoxyn label) (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion. (1)

None (41) · Rx-only (1) · Rx-only in US (1) · Schedule II (4) · Schedule IV (US) (1)